Clinical development plan patient numbers

Between mid-1792 and late 1793 Beddoes published a number of works, which set out the theoretical basis for his plans to develop pneumatic medicine. That basis lay primarily in the notion of regulating the atmosphere, that is, adjusting (in experimental and clinical situations) the amount of oxygen that the breathed atmosphere contained, or at least the amount of oxygen taken in by patients. See, in particular, T. Beddoes, Observations on the Nature and Cure of Calculus, Sea Scurvy, Consumption, Catarrh and Fever Together with Conjectures upon Several other subjects of Physiology... 

A purified version of pluronic F68 is being developed by SynthRx under the brand name Flocor as a potential treatment of vaso-occlusive crisis associated with sickle cell disease [172]. After establishing the tolerability of this polymer in clinical studies, further studies of sickle cell patients treated with Flocor showed a reduction in the length of painful episodes and an increase in the number of patients who achieved resolution of the symptoms [173]. The effect observed was significant but small, and the effects seen were more pronounced for children imder the age of 15. Further development of Flocor has been reportedly planned, especially for pediatric sickle cell patients. 

---